key: cord-0810437-fyurw6t6
authors: Siscel, Jordan; Short, Margo; Flynn, Brigid
title: Understanding ST-elevation myocardial infarction in COVID-19: the marriage of bench work and big data
date: 2021-06-06
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.06.002
sha: ffee261db2c0dd872b7b1325def14f597a2e7c3f
doc_id: 810437
cord_uid: fyurw6t6

nan

COVID 19 has led to substantial morbidity and mortality around the world and altered healthcare delivery in nearly every hospital in every country. While COVID 19 infection is commonly thought to primarily effect the pulmonary system, the cardiovascular effects cannot be disregarded. [1] [2] [3] Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) is the virus responsible for COVID 19. It is the third beta-coronavirus to cause an infectious outbreak. Each of these epi-or pandemics caused by beta-coronaviruses have involved not only respiratory manifestations among those infected, but also significant effects on the cardiovascular system.

The first known beta-coronavirus epidemic was in 2003, when SARS-CoV-1 led to the outbreak of SARS and was noted to commonly cause hypotension and tachycardia. 1 Some patients suffered more severe cardiac manifestations, including arrhythmia, cardiomegaly, diastolic dysfunction, direct damage to the myocardium, vasogenic shock and unstable coronary plaques. In 2012, the Middle East Respiratory Syndrome Coronavirus (MERS) outbreak caused acute myocarditis, myocardial edema and left ventricular dysfunction in some infected patients. 1 Similar to its beta-coronavirus predecessors, COVID 19 leads to cardiac manifestations, however the common presentation differs and the severity is enhanced. With COVID 19, myocardial injury is in the form of STEMI or NSTEMI is the predominant cardiac manifestation with an estimated incidence of 7.2% to 27.8% in patients who have COVID 19. 1 A potential reason for the association of myocardial infarction with COVID may be due to the mechanism in which SARS-CoV-2 enters cells in order to replicate. Both SARS-CoV-1 and SARS-CoV-2 bind to the angiotensin converting enzyme (ACE)2 receptor. However, SARS-CoV-2 has a 10-20 fold greater affinity for this receptor compared to SARS-CoV-1. 4 ACE2 receptor is expressed on many tissues, including the upper airway, which allows for inhalational and droplet entry, the lungs, leading to pulmonary manifestations, and the heart. 4 Not only does SARS-CoV-2 likely lead to direct myocardial injury within myocytes, it also has negative effects on the renin angiotensin aldosterone system (RAAS) due to ACE2 receptor binding.

As SARS-CoV-2 binds to the ACE2 receptor, the available number of ACE2 receptors decrease. This is important since the ACE2 receptor is responsible for downregulation of the RAAS system. While the mechanisms are still being elucidated, it is possible this binding results in unhindered RAAS action leading to vasoconstriction and aldosterone release, which could both have negative effects on cardiac function. 4 RAAS activation also activates endothelium to upregulate von Willebrand factor, leading to platelet and complement activation. Activated platelets recruit neutrophils to release neutrophil extracellular traps (NETs) which are webs of chromatin, microbicidal proteins and oxidant enzymes. 5 While NETs are meant to contain infections, NETs can also promote excessive inflammation and clotting and have been associated with arterial and venous thrombosis, disseminated intravascular coagulopathy and vasculitis. Importantly, NETs have been found to be elevated in patients with COVID. 6 All of these components of unbridled RAAS activation may be one of many etiologies behind the notable incidence of thrombotic complications in patients with COVID 19 infection.

While most viruses lead to an inflammatory state, COVID appears to be extremely prothrombotic with 34% of critically ill patients with COVID suffering thrombotic complications despite being on anticoagulant thromboprophylaxis. 7 This large percentage does not include the unmeasured microthromboses, including those in the coronary vasculature, that are likely occurring simultaneously.

For patients who do suffer myocardial infarctions, the COVID pandemic presented particular challenges in the diagnosis and management of acute coronary syndrome. The reasons for this are two-fold: 1) difficulty in correct diagnosis due to the overlap of symptoms with COVID and myocardial infarction, especially dyspnea and chest pain, and 2) the immediate need for reorganization and triage of every hospitalized patient in order to treat patients with COVID and to mitigate the spread of COVID 19. 8 Thankfully, many researchers were able to quickly organize collaborations and create large registries and databases aimed at understanding how the pandemic affected the healthcare system and specific patient populations. Several such registries took a granular approach and focused on patients who suffered ST-elevated myocardial infarction (STEMI).

Authors have recently begun to publish initial registry and database findings concerning the implications of the COVID 19 pandemic on the diagnosis, treatment and outcomes of patients who sustained STEMI. The largest such North American registry was created by three major cardiovascular societies (Society for Cardiovascular Angiography and Interventions (SCAI),

Interventional Council) which collaborated to establish the North American COVID-19

Myocardial Infarction (NACMI) Registry. The aim was to clarify the effect of the pandemic on the clinical management of acute coronary syndrome. 9 The NACMI registry is a prospective, investigator-initiated, multicenter observational registry of patients specifically hospitalized with STEMI and who have confirmed or suspected COVID infection. It includes 64 sites, of which 52 are located in the United States while 12 are located in Canada. Initial findings were published for patients admitted between January 1st, 2020 to December 6th, 2020. 10 In this analysis, demographic characteristics, management strategies and outcomes of patients in the registry (230 patients with confirmed COVID and 495 patients under investigation (PUI)) were compared to a control group of STEMI patients without COVID infection treated 5 years before the pandemic (460 patients) and included in the Midwest STEMI Consortium. Patients were matched based on age and gender in a 2:1 ratio of control (pre-pandemic) to case-matched NACMI registry patients.

Patients who had a STEMI in the setting of infection with COVID were typically male (71%) and between 56 and 75 years of age. The majority of COVID positive patients were ethnic minorities (61%). The COVID positive cohort was more likely to have diabetes, but less likely to have other coronary artery disease risk factors compared to the control group, including dyslipidemia, a history of smoking, previous percutaneous intervention (PCI) or previous myocardial infarction. Additionally, presentation was more atypical with the COVID positive STEMI patients presenting with a higher percentage of dyspnea rather than chest pain.

When compared to historical non-COVID controls with STEMI, the COVID positive STEMI patients were more likely to have pulmonary infiltrates on chest x-ray and more likely to be sicker pre-PCI as evidenced by a higher rate of cardiac arrest and cardiogenic shock.

The primary endpoint of the study was the difference in a composite of in-hospital death, stroke, recurrent infarction and unplanned revascularization which was statistically higher in the COVID positive group with a rate of 36% compared to the control group rate of 5%. In-hospital mortality rate of the COVID group was 33% which was significantly higher than the control group (4%). It remains unclear if the COVID STEMI patients died due to pulmonary, cardiovascular or other etiology of death. This is an important distinction as the reported incidence of death from COVID in intensive care unit patients, not considering any other morbidities, is nearly 39%. 11 Central discussion points of this initial publication concerned the variance in management of the COVID STEMI patients when compared to control patients who suffered STEMI prior to the pandemic. During the pandemic, only 78% underwent angiography (compared to 100% of the control) and when they did receive angiography the door-to-balloon time was prolonged (79 minutes vs. 66 minutes). Interestingly, the COVID positive patients were less likely to receive PCI than control patients (71% vs. 93%). This may have been due to the high rate of no culprit lesions found on angiography in patients with STEMI in the setting of COVID infection (23% vs. 1%). Medical treatment alone was prescribed to 20% of patients with COVID, whereas only 2% of STEMI patients prior to the pandemic were prescribed medical management without intervention.

The NACMI registry is just one of the many ongoing registries attempting to provide insight on the management of cardiovascular disease during the COVID 19 pandemic. The differences in these registries highlight potential limitations in the NACMI registry. Recently, Lala, et al. examined patients from the five hospitals in the Mt. Sinai Health System in New York. 12 Rather than analyzing based on therapy offered for STEMI patients, this study focused on incidence of increased troponin levels and outcomes in hospitalized COVID 19 patients. The study found that 36% of hospitalized COVID 19 patients had elevated troponin levels, representing myocardial injury. Furthermore, elevated troponin levels in COVID patients were significantly associated with higher in-patient mortality.

When compared with the NACMI registry, which included both known and suspected COVID patients, databases such as the one described by Lala, et al., that limit enrollment to COVID patients only, instead of analyzing PUI's, offer less confusing results. In addition, comparing patients with acute coronary syndrome who were positive for COVID with contemporaneous patients who were COVID negative may have benefit. In other words, the NACMI comparison of pre-pandemic STEMI patients to pandemic STEMI patients may lead to confounding findings. This is due to the possibility that STEMI patients during the pandemic actually fared differently -even if they were COVID negative -than historical STEMI patients from five years ago. In other words, the North American healthcare system encountered challenges in treating all patients, regardless of COVID status. Thus, STEMI patients who did not have COVID also had their care impacted during the pandemic compared to previous cohorts. 13 Furthermore, the effect of delayed presentation for coronary syndromes during the pandemic likely had an equally negative compounding effect on patients with and without COVID. Hence, the outcome analysis by Garcia, et al., would be altered if, indeed, contemporary, non-COVID STEMI patients also had poor outcomes that could not be attributed to COVID infection, but were an unfortunate sequelae of limitations on medical care incurred during to the pandemic. This notion is corroborated by another registry titled the International Study on Acute Coronary Syndromes (ISACS) STEMI COVID-19 registry which was created in Europe with similar intentions to the NACMI registry. 14 The ISACS registry is much larger than the NACMI registry, including 6,609 patients versus 1,185 patients, respectively. Unlike the NACMI, the ISACS STEMI registry included only STEMI patients who underwent interventional treatment with PCI.

Also different is that the ISACS STEMI registry included patients regardless of COVID status. In other words, contemporary non-COVID controls were included in the registry. These key differences allow for secondary and sub-analyses via alternative angles on how the pandemic effected cardiovascular care in STEMI patients.

Similar to the NACMI registry study, the ISACS STEMI analysis compared patient outcomes utilizing two finite time points of intra-versus pre-pandemic. And, similarly, the ISACS STEMI researchers observed a significantly higher mortality in 2020 as compared with pre-pandemic mortality in 2019 (6.8% vs. 4.9%, OR: 1.41). Furthermore, the mortality rate was much higher among patients testing positive for COVID with 29% of COVID positive patients succumbing to death versus 5.5% of COVID negative patients dying (OR: 7.0). Importantly, the poor outcomes observed in patients with STEMI treated during the pandemic persisted after correction for all potential confounding factors (geographic area, direct access by ambulance, ischemia time, door-to-balloon, radial access, type of stent). This disparity in outcomes following PCI remained even after exclusion of patients who tested positive for COVID 19. These findings illustrate that it may not be prudent to compare STEMI outcomes during the 2020 pandemic with STEMI outcomes from historical controls as was conducted by the NACMI registry analysis.

The ISACS STEMI registry team also identified that during the pandemic, as expected, there was a significant reduction in PCI as compared with pre-pandemic PCI. Interestingly, this reduction was not related to the incidence of COVID disease within the particular institution or to the number of COVID positive patients, at both local and national levels in these European centers. Unfortunately, the incidence of PCI within the specific Canadian and U.S. sites in the NACMI registry was not reported, but would be an interesting data point as this, too, could affect STEMI outcomes.

While there is no perfect registry, database or study, researchers are beginning to identify important signals from these analyses. Equally of import, understanding distinct mechanisms related to the notable incidence of myocardial infarction in patients with COVID, especially concerning the ACE2 receptor and RAAS dysregulation, is advancing rapidly. Bridging of this molecular work alongside the registry and database findings is important in order to understand the clinical presentations and the optimal treatment options for patients with COVID and cardiovascular dysfunction. The collaborations that quickly formed among countries and hospitals in order to achieve a large volume of patient data during the pandemic is commendable. Researchers who partook in these efforts will aid the on-going treatment of COVID patients.

Unfortunately, these impressive efforts in studying COVID 19 may need to be revised and reinvented in a future pandemic. Epidemiologists fear that zoonotic diseases, such as COVID 19, will continue to occur. If past holds true, the severity of each outbreak, including cardiac manifestations, may be unfathomably worse than the one before. And, just as in the past, the weapon that scientists and physicians will need most, will be data collection and analysis in order to save lives.

Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications

Cardiovascular Consequences and Considerations of Coronavirus Infection -Perspectives for the Cardiothoracic Anesthesiologist and Intensivist During the Coronavirus Crisis

Critical Care During the Coronavirus Crisis: Challenges and Considerations for the Cardiothoracic and Vascular Anesthesia Community

Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar

The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review

Outcomes and Risk Factors for Cardiovascular Events in Hospitalized COVID-19 Patients

North American COVID-19 ST-Segment

Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications

Initial Findings From the North American

Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

Protecting High-Risk Cardiac Patients During the COVID-19 Outbreak

Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: